Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
Michael S Albosta,Jelani K Grant,Pam Taub,Roger S Blumenthal,Seth S Martin,Erin D Michos
DOI: https://doi.org/10.2147/VHRM.S338424
2023-07-07
Vascular Health and Risk Management
Abstract:Michael S Albosta, 1 Jelani K Grant, 2 Pam Taub, 3 Roger S Blumenthal, 2 Seth S Martin, 2 Erin D Michos 2 1 Internal Medicine Department, University of Miami Miller School of Medicine/ Jackson Memorial Hospital, Miami, FL, USA; 2 Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 3 Division of Cardiology, University of California San Diego, San Diego, CA, USA Correspondence: Erin D Michos, Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Blalock 524-B, 600 N. Wolfe Street, Baltimore, MD, 21287, USA, Tel +1 410-502-6813, Email Multiple lines of evidence confirm that the cumulative burden of low-density lipoprotein cholesterol (LDL-C) is causally related to the development of atherosclerotic cardiovascular disease (ASCVD). As such, lowering LDL-C is a central tenet in all ASCVD prevention guidelines, which recommend matching the intensity of LDL-C lowering with the absolute risk of the patient. Unfortunately, issues such as difficulty with long-term adherence to statin therapy and inability to achieve desired LDL-C thresholds with statins alone results in residual elevated ASCVD risk. Non-statin therapies generally provide similar risk reduction per mmol/L of LDL-C reduction and are included by major society guidelines as part of the treatment algorithm for managing LDL-C. Per the 2022 American College of Cardiology Expert Consensus Decision Pathway, patients with ASCVD are recommended to achieve both an LDL-C reduction ≥ 50% and an LDL-C threshold of < 55 mg/dL in patients at very high-risk and < 70 mg/dL in those not at very high risk. Patients with familial hypercholesterolemia (FH) but without ASCVD should lower LDL-C to < 100 mg/dL. For patients who remain above LDL-C thresholds with maximally tolerated statin therapy plus lifestyle changes, non-statin therapy warrants strong consideration. While several non-statin therapies have been granted FDA approval for managing hypercholesterolemia (eg, ezetimibe, Proprotein Convertase Subtilisin/Kexin 9 [PCSK9] monoclonal antibodies, and bempedoic acid), the focus of the current review is on inclisiran, a novel small interfering RNA therapy that inhibits the production of the PCSK9 protein. Inclisiran is currently FDA approved as an adjunct to statin therapy in patients with clinical ASCVD or heterozygous FH who require additional LDL-lowering. The drug is administered by subcutaneous injection twice a year, after an initial baseline and 3 month dose. In this review, we sought to provide an overview of the use of inclisiran, review current trial data, and outline an approach to potential patient selection. Keywords: inclisiran, lipids, cardiovascular disease prevention, LDL-cholesterol Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in the United States (U.S.) 1 and globally. 2 ASCVD affects approximately 24 million Americans, or 1 in 10 persons older than 21 years, 3 and ASCVD death rates have been increasing in the US since 2010. 1 There is compelling evidence from genetic studies, observational data, and interventional studies that low density lipoprotein cholesterol (LDL-C) is causally related to ASCVD. 4 As such, lowering LDL-C remains the cornerstone for ASCVD prevention across all major society guidelines. 5,6 The cumulative burden of LDL-C, meaning the magnitude of LDL-C elevation times the years of exposure to that level, nicknamed "cholesterol-years", is directly related to ASCVD risk. 7,8 Atherosclerotic plaques progress over time proportional to a person's cumulative exposure to atherogenic lipids such as LDL-C and other apolipoprotein B (apoB) containing lipoproteins; 8 thus, it is important to achieve lower LDL-C earlier in life and maintain lower levels for longer periods of time. In addition to healthy lifestyle measures, statins remain the first line pharmacotherapy for managing LDL-C for the purposes of ASCVD prevention. 5,6,9 Data from the Cholesterol Treatment Trialist's meta-analysis of statin trials suggest that for every 1 mmol/L reduction in LDL-C, there is an approximate 20–25% reduction in vascular events. 10 Furthermore, the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial demonstrated a 44% relative risk reduction (RRR) [absolute risk reduction (ARR) 1.2%; number needed to treat (NNT) 169 over a median 1.9 years] in first major adverse cardiovascular events (MACE) in primary prevention patients with elevate -Abstract Truncated-